
|Articles|May 30, 2019
Speaking with David Van Sickle, CEO, Propeller Health
David Van Sickle, CEO, Propeller Health, talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about how the digital therapeutics landscape has changed.
Advertisement
David Van Sickle, CEO, Propeller Health, talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about how the digital therapeutics landscape has changed.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
3
Report: Richard Pazdur Out as Director of CDER
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5





